Related Experiment Video
Updated: Jun 19, 2026
06:38
Use of a Piglet Model for the Study of Anesthetic-induced Developmental Neurotoxicity (AIDN): A Translational Neuroscience Approach
Published on: June 11, 2017
Proposals for model-based paediatric medicinal development within the current European Union regulatory framework
Efthymios Manolis1, Gérard Pons
1Scientific Advice and Orphan Drugs, European Medicines Agency, London, UK. efthymios.manolis@emea.europa.eu
British Journal of Clinical Pharmacology
|October 22, 2009
Summary
Modelling and simulation (M&S) offers advanced techniques for drug development in children, addressing ethical and regulatory demands. Optimizing M&S integration in regulatory processes is crucial for efficient paediatric medicine development.
Area of Science:
- Pharmacology
- Regulatory Science
- Paediatric Medicine
Background:
- New European Union (EU) regulations mandate paediatric studies, increasing the need for efficient drug development in children.
- Ethical considerations require minimizing the burden of clinical trials on paediatric populations.
- Modelling and simulation (M&S) presents a valuable approach to overcome challenges in paediatric drug development.
Purpose of the Study:
- To explore the regulatory framework for M&S in paediatric medicinal development.
- To propose strategies for model-based paediatric drug development.
- To foster discussion among stakeholders on the optimal use of M&S in this field.
Main Methods:
- Review of the regulatory landscape for M&S in paediatric drug development.
- Analysis of the utility of M&S in addressing sparse data and predicting pharmacokinetics/pharmacodynamics (PK/PD).
- Extrapolation of data from adult to paediatric populations and interpolation between paediatric age subsets.
Main Results:
- M&S enables quantitative analysis of sparse data, characterization of PK/PD, and extrapolation/interpolation of drug effects.
- Industry, academia, and regulators acknowledge the benefits of M&S in paediatric drug development.
- Current integration of M&S into EU regulatory decision-making is limited, with expertise concentrated in specific sectors.
Conclusions:
- M&S is a vital tool for optimizing paediatric drug safety and efficacy assessment.
- Enhanced integration of M&S into regulatory frameworks is necessary for efficient paediatric medicine development.
- Open dialogue between industry, academia, paediatricians, and regulators is essential for advancing model-based paediatric drug development.
Related Concept Videos
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
01:28Preclinical Development: Overview
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
01:25Drug Regulation
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
01:27Pharmacodynamic Models: Overview
Pharmacodynamic (PD) responses describe the interaction between a drug and its biological target, culminating in a physiological effect. These responses can be classified into different types: continuous variables, such as blood glucose levels; categorical outcomes, like survival rates; and time-to-event metrics, such as disease progression. Understanding and modeling PD responses are critical for optimizing drug efficacy and safety.PD models describe the relationship between drug concentration...
01:29Clinically Relevant Drug Product Specifications: Methods of Establishment
Product specifications define the acceptable quality of a pharmaceutical product by ensuring identity, purity, potency, and strength. These specifications serve as benchmarks during development, manufacturing, and post-approval quality control. Clinically relevant specifications are particularly important because they directly relate to a drug's safety and efficacy in clinical use.Dissolution studies are critical biopharmaceutic tools that link in vitro behavior to in vivo performance. They...